Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
A Phase 3 Trial of Brepocitinib in Dermatomyositis.
Journal: The New England journal of medicine
Published: March 30, 2026
A Phase 3 Trial of Brepocitinib in Dermatomyositis.
Journal: The New England journal of medicine
Published: March 30, 2026
Correction: Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02).
Journal: Journal of neurology
Published: February 17, 2025
Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study.
Journal: The Lancet. Neurology
Published: September 06, 2024
The Results of ADVANCE-CIDP IVIG Trial: Intravenous Immunoglobulin 10% Therapy With GAMMAGARD LIQUID/Kiovig for Treatment of Relapse in Chronic Inflammatory Demyelinating Polyradiculoneuropathy.
Journal: European journal of neurology
Published: August 16, 2024
Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study.
Journal: Therapeutic advances in neurological disorders
Published: October 17, 2023
Long-term safety and efficacy of cipaglucosidase alfa plus miglustat in individuals living with Pompe disease: an open-label phase I/II study (ATB200-02).
Journal: Journal of neurology
Published: August 17, 2023
Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.
Journal: The Lancet. Neurology
Published: November 10, 2022
Long-term safety and tolerability of bimagrumab (BYM338) in sporadic inclusion body myositis.
Journal: Neurology
Published: October 22, 2019
Congenital myasthenic syndrome caused by a frameshift insertion mutation in GFPT1.
Journal: Neurology. Genetics
Published: May 22, 2019
Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial.
Journal: The Lancet. Neurology
Published: February 06, 2019
Last Updated: 09/26/2026